Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Mary Patricia Pauly"'
Autor:
Laura C. Gittleman, Michael J. Silverberg, Joanna Ready, Mary Patricia Pauly, Jennifer O Lam, Scott Chamberland, Daniel G. Korn, Julia L. Marcus, Jamila H. Champsi, Jennifer B. Lai, Suk I. Seo, Leo B. Hurley, Charles P. Quesenberry, Varun Saxena, David J. Witt
Publikováno v:
Clinical Gastroenterology and Hepatology. 16:927-935
BACKGROUND & AIMS: Treatment with the combination of ledipasvir and sofosbuvir for 12 weeks has been approved by the Food and Drug Administration for patients with genotype 1 hepatitis C virus (HCV) infection; some patients can be treated with an 8-w
Autor:
Mary Patricia Pauly, Jennifer B. Lai, Suk I. Seo, Maxwell A. Witt, Michael Allerton, David J. Witt, Joanna Ready
Publikováno v:
Drugs. 77:313-318
Second-generation direct-acting antiviral agents are integral to treatment of hepatitis C (HCV) infection. Eight-week courses of ledipasvir/sofosbuvir (LDV/SOF) have been supported in some studies, but data are limited on efficacy in real-world use.
Autor:
Scott Chamberland, David R. Witt, C. Bradley Hare, Varun Saxena, Suk I. Seo, Michael J. Silverberg, Mary Patricia Pauly, Joanna Ready, Julia L. Marcus, Leo B. Hurley, Daniel G. Korn, Jamila H. Champsi, Jennifer B. Lai
Publikováno v:
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 18(2)
Strategic planning for hepatitis C virus (HCV) screening and treatment requires up-to-date information on the prevalence of HCV spontaneous clearance. Published estimates of HCV spontaneous clearance range from 15% to 60%.1-3 We conducted an observat
Autor:
Joanna Ready, Anna S.F. Lok, Jessica P. Hwang, David Baer, Mary Patricia Pauly, Lue Yen Tucker, Jean Luc Szpakowski
Publikováno v:
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 16(12)
Background & Aims Tumor necrosis factor (TNF) antagonists are the first-line treatment for many autoimmune diseases. However, they have been associated with reactivation of hepatitis B virus (HBV). We determined the rate of HBV reactivation and hepat
Publikováno v:
Journal of Hepatology. 66:S516
Autor:
Lisa Catalli, Valentina A. Shvachko, E. Wayne, H. S. Yee, Mary Patricia Pauly, M. Michele Manos, Rosemary C. Murphy, Varun Saxena, Norah A. Terrault, J. Chua, Alexander Monto
Publikováno v:
Alimentary pharmacology & therapeutics, vol 39, iss 10
Summary Background Risks and benefits of protease inhibitor (PI) (telaprevir or boceprevir) triple therapy in hepatitis C virus (HCV)-infected patients with mildly decompensated cirrhosis, including those wait-listed for liver transplantation (LT), a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed972c6eeed81328c3659179f2f1e382
https://escholarship.org/uc/item/36r010bj
https://escholarship.org/uc/item/36r010bj
Autor:
Norah A. Terrault, Barbara Piasecki, Varun Saxena, Aditi Dasgupta, L. Nyberg, Joanna Ready, A. Nyberg, Mary Patricia Pauly, Robert Rathbun, Lisa Catalli, Stephanie Straley, Kali Sommer, Gayle Witt, Jean-Luc Szpakowski, Bradley J. Winston, Jacquelyn L. Redd
Publikováno v:
Journal of Hepatology. 62:S669-S670
Autor:
Constance Chia, Marcia Russell, Jennifer Mary Dorrell, Charles Moore, Renee Junko Cunanan, Gayle Witt, Mary Patricia Pauly
Publikováno v:
Drug and alcohol dependence. 134
The relation of drug use to HCV treatment outcome in an insured household population has not been previously reported.Lifetime frequencies of marijuana use and non-medical use of stimulants, sedatives, and opioids; hallucinogens; and inhalants were r
Publikováno v:
Journal of Hepatology. 64:S616
Autor:
Antonio Monarca, Peled Y, Boris H. Ruebner, Valeria Azzolini, B. A. Runyon, John M. Vierling, Neville R. Pimstone, J. Rattan, Robert H. Fennell, Mary Patricia Pauly, Roberto Natangelo, Z. Fireman, Richard E. Ward, Tuvia Gilat
Publikováno v:
Hepatology. 7:203-206